Get your free ETF data sample from our comprehensive offerings. Start your free trial→

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

›ETF Providers›VanEck›BBH
ETF screener
BBH
US92189F7261
Passive ETFEquity

BBH ETF · VanEck Biotech ETF

The BBH Exchange Traded Fund (ETF) is provided by VanEck. It is built to track an index: MVIS US Listed Biotech 25 Index. The BBH ETF provides physical exposure, so by buying it you actually own parts of all the 24 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 5/8/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.-0.63%
Last price
$184.60
1M perf.
-2.82%
1M flows
-€4.8M
AuM
€307M
TER
0.35%
Rating
ESG Consensus®
esg grade icon
BBH
$184.60

Performance & flows

Segment for quartile rank
February 9, 2026 → May 8, 2026
0-10-8-6-4-202%MARAPRMAYMARAPRMAY
Create a free account to view the flows graph
BBH
$184.74
-6.74%
US Health Care
-5.27%

Historic performance and flows

1M3M1Y3Y5YMTDQTDYTD
Perf.
-2.82%
icon
-6.74%
icon
+29.66%
icon
+18.10%
icon
+7.08%
icon
-0.38%
-1.74%
-2.35%
icon
Flows

Key fund info

Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) Â· 
Main characteristics
Issuer
CUSIP
92189F726
ISIN
US92189F7261
AuM
€307M
icon
TER
0.35%
icon
Replication rating
icon
ESG Consensus®
esg grade icon
icon
More details
NAV
5/8/2026
$184.74
1D NAV change
-0.36%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
24
Inception date
12/20/2011
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Fund
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Asset class
Factors
N/A
Investment strategy
VanEck Vectors® Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
half moonhalf moon double
New to Trackinsight?
For individual investors

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors

Trackinsight
Enterprise

Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trial
More professional services:ETF Data ServicesDue Diligence Services

Similar ETFs in your region

SLTY
1M perf.
-5.44%
TER
1.24%
FTXH
1M perf.
-2.02%
TER
0.6%
RSPH
1M perf.
-1.50%
TER
0.4%
IYH
1M perf.
-3.74%
TER
0.38%
FHLC
1M perf.
-0.59%
TER
0.08%

Advertisement

Risk profile

Segment for quartile rank

Historical risk/return profile

3M1Y3Y5Y
Returns
-6.74%
icon
+29.66%
icon
+18.10%
icon
+7.08%
icon
Volatility
Perf./Volatility
Max drawdown
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries
USA
97.60%
Ireland
1.24%
Netherlands
1.16%
Sectors
Health Care
89.52%
Unavailable
10.48%
Diversification
Total weight of top 15 holdings out of 24
Top 15 holdings
Data as of March 31, 2026
AMGEN-T
GILEAD SCIENCES
VERTEX PHARMACEUTICALS
REGENERON PHARMACEUTICALS
US04016X1019
INSMED
IQVIA HOLDINGS INC
ALNYLAM PHARMACEUTICALS
Create a free account to view top holdings
BIOGEN INC
UTD THERAPEUT
NATERA
US07725L1026
MODERNA INC
REVOLUTION MEDICINES INC
ILLUMINA
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria
No
SDG

ESG Consensus® by Conser

Data as of February 27, 2026
Methodology

Our partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about BBH ETF's sustainability, based on their methodology.

Learn more about Conser

ESG Consensus®
esg grade icon

ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.


BBH’s has a Final Sustainability Grade of either B+, B, or B-.

This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight Enterprise
Holdings review
85.12% of holdings have positive scoring
14.87% of holdings have negative scoring
8.39%
56.95%
19.78%
7.65%
7.22%
Consensus levels
Strong
Medium
Weak
No data on remaining < 1% of holdings
More sustainability metrics are available, exclusively in Trackinsight Enterprise

Replication

Trackinsight replication rating:
1-year trailing difference
As of April 30, 2026
Create a free account to view the replication graph
BBH
N/A
Replication quality
Calculated over 12m, as of April 30, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model

Issuer

VanEck
VanEck ID Card
Number of funds
182
Total AuM
€197.33B
Expense ratio range
0.07% - 12.86%
Average expense ratio
0.6644%

Through forward-looking, intelligently designed active and ETF solutions, VanEck offers value-added exposures to emerging industries, asset classes and markets as well as differentiated approaches to traditional strategies. Global player based in New York, founded in 1955, ranked among the 10 best providers of ETFs in the United States, VanEck also has a strong presence in Europe (Germany, Switzerland, the Netherlands) as well as a presence in Asia and Australia. VanEck is different from other asset managers by being privately held, allowing them to focus on clients’ long-term interests, constantly been at the forefront of innovation and whose ETFs are transparent with no synthetic replication and no lent out.

Via Offical website

Frequently asked questions about BBH

What does VanEck Biotech ETF, BBH, invest in?

BBH is a Passive ETF. This ETF provides exposure to US Biotechnology Equities.

Which benchmark or index does BBH replicate?

BBH tracks the MVIS US Listed Biotech 25 Net Total Return Index - USD, through a full replication replication method.

What is the Total Expense ratio (TER) of BBH?

BBH carries a total expense ratio (TER) of 0.35%, indicating the annual cost for holding the fund.

When was BBH launched?

BBH was introduced to the market on December 20, 2011. It trades on United States

Who is the ETF issuer of BBH?

VanEck Biotech ETF, BBH, is provided by VanEck. Learn more about VanEck here.

What is the current assets under management (AUM) of BBH?

BBH oversees €307M in assets as of May 8, 2026.

How has BBH performed lately?

Based on data from May 8, 2026, BBH returned -2.82% over the past month, -6.74% over the last three months and -2.35% year-to-date.

What are the latest inflows or outflows for BBH?

As of May 8, 2026, BBH recorded net flows of -€4.8M over the last month and -€6.1M year-to-date.

Does BBH distribute dividends?

BBH follows a distributing dividend policy, meaning it pays out income to investors. As of May 8, 2026, its 12-month trailing yield was 0.52%.

What are the main country or region exposures of BBH?

As of March 31, 2026, BBH has significant geographic allocations in USA, Ireland and Netherlands.

In which sector or theme does BBH invest in?

As of March 31, 2026, BBH focuses largely on Health Care.

How many securities does BBH hold and how diversified is it?

As of March 31, 2026, BBH holds 24 positions in its portfolio, with 86.44% of assets concentrated in its top 15 holdings.

What are the main positions in BBH?

As of March 31, 2026, BBH top three holdings include AMGEN-T, GILEAD SCIENCES and VERTEX PHARMACEUTICALS.

What is the base currency of BBH?

The base currency of BBH is USD.

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight